摘要:
The present invention relates to somatotropin analogues with amino acid changes in the alpha-helix 1 regions of said somatotropins, alone or in combination with mutations in the alpha-helix 3 and/or alpha-helix 2 regions, plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptide also are provided.
摘要:
The present invention relates to somatotropin analogues with amino acid changes in the alpha-helix 1 regions of said somatotropins, alone or in combination with mutations in the alpha-helix 3 and/or alpha-helix 2 regions, plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptide also are provided.
摘要:
The present invention relates to novel modified or derivatized recombinant animal somatotropins. This invention also provides methods for stabilizing recombinant animal somatotropins by modification or deletion of the Cysteine residues utilizing site directed mutagenesis to replace from one to four of the cysteine amino acid residues of said somatotropins with one or more different amino acid residues or by derivatization of (1) both cysteine amino acid residues in the small loop of said somatotropin, both cysteine amino acid residues in the large loop or the four cysteine amino acid residues in both loops of said somatotropin.
摘要:
The present invention relates to somatotropin analogues with amino acid changes in the α-helix 3 regions of said somatotropins, changes in the α-helix 2 regions, combinations thereof plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptides also are provided.
摘要:
The present invention relates to somatotropin analogues with amino acid changes in the α-helix 3 regions of said somatotropins, changes in the α-helix 2 regions, combinations thereof plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptides also are provided.
摘要:
The present invention relates to novel modified or derivatized recombinant animal somatotropins. This invention also provides methods for stabilizing recombinant animal somatotropins by modification or deletion of the Cysteine residues utilizing site directed mutagenesis to replace from one to four of the cysteine amino acid residues of said somatotropins with one or more different amino acid residues or by derivatization of (1) both cysteine amino acid residues in the small loop of said somatotropin, both cysteine amino acid residues in the large loop or the four cysteine amino acid residues in both loops of said somatotropin.